Comparison between different risk scores
| D:A:D* (n=362) n (%) | FRS† (n=382) n (%) | ASCVD‡ n (%) | QRISK2§ (n=376) n (%) | RAMA-EGAT (n=376) n (%) | |
| Risk profile | |||||
| High | 9 (2.5) | 33 (16.3) | |||
| Intermediate | 123 (33.9) | 19 (9.4) | |||
| Low | 230 (63.5) | 150 (74.3) | |||
| Kappa statistic | 1 | – | 0.25 | – | – |
| Risk per cent | |||||
| >20 | 12 (3.1) | 3 (1.5) | 13 (3.5) | 2 (0.5) | |
| 10–20 | 28 (7.3) | 18 (8.9) | 30 (7.9) | 62 (16.5) | |
| <10 | 342 (89.5) | 181 (89.6) | 333 (88.6) | 312 (82.9) | |
| Kappa statistic | – | 1 | 0.48 | 0.67 | 0.57 |
| Percent difference in 10-year cumulative risk scores ¶ | 12.8 | – | 36.5 | ||
| Lifetime risk | |||||
| <50% | – | 355 (92.9) | 292 (80.9) | 252 (67) | – |
| ≥50% | 27 (7.1) | 69 (19.1) | 124 (32.9) | ||
| Statin recommended | |||||
| Yes | – | – | 64 (32.0) | 43 (11.4) | – |
| No | 138 (68.0) | 333 (88.6) |
All scores except the D:A:D score estimate a 10-year CVD risk.
*D:A:D score estimates a 5 -year CVD risk. High risk (>5%), intermediate risk (1%–5%), low risk (<1%).
†FRS: Lifetime risk was derived using the Framingham 30-year CVD risk with lipids. Ten-year risk was derived using the score with lipids.
‡ASCVD: 10-year risk estimation and statin recommendations for 40–79 years (n=202). Lifetime risk estimated for 20–59 years (n=361). High risk (≥7.5%), intermediate risk (5%–7.5%), low risk (<5%).
§QRISK2: Lifetime risk estimation was done using the QRISK lifetime CVD risk calculator, statin recommendations were based on NICE guidelines.
¶Per cent difference was calculated as: ((cumulative CVD risk of study population - cumulative CVD risk of normal population)/ cumulative CVD risk of normal population)*100. The risks for the normal populations were abstracted from the risk calculators of the respective scores from their official websites.
ASCVD, Atherosclerotic Cardiovascular; CVD, cardiovascular disease; D:A:D, Data Collection on Adverse Effects of Anti-HIV Drugs Study; FRS: Framingham risk score; NICE, National Institute for Health and Care Excellence; RAMA-EGAT, Ramathibodi—Electricity Generating Authority of Thailand score.